Document Detail

Assessment of GDNF in primate models of Parkinson's disease: comparison with human studies.
MedLine Citation:
PMID:  16519007     Owner:  NLM     Status:  MEDLINE    
Potential future treatments for Parkinson's disease (PD) include those that not only provide symptomatic relief to patients but are also neuroprotective and/or neurorestorative. Glial cell line-derived neurotrophic factor (GDNF) may be a valuable candidate in this regard. Positive results using monkeys have encouraged the use of GDNF in human trials. These trials have unfortunately shown mixed results, illustrating the influence that various parameters of administration can have on clinical outcome. The aim of this review is to compare the findings of these clinical studies with available primate data. While bolus intraventricular injections of GDNF in primates have shown some behavioural efficacy, there was no clinical benefit in the first human trial using this method, which was most likely a result of inefficient GDNF distribution in the striatal parenchyma. In primates, however, continuous (rather than bolus) delivery of GDNF into the ventricles results in significant distribution in the striatum. While chronic delivery of GDNF into the ventricles has not been assessed in humans, intraputamenal protein delivery in two Phase I trials have demonstrated that GDNF considerably reduces PD symptoms, suggesting that the putamen is the optimal location for delivery. Primate studies have shown that vector mediated delivery of GDNF may provide a suitable means for long-term intraputamenal delivery. However, the possibility of high levels of GDNF resulting in widespread distribution of GDNF to non-targeted areas is a cause of concern, and vectors with transgene regulation are needed. The development of these vectors may be the way forward for GDNF treatment.
Andisheh Eslamboli
Related Documents :
15485097 - Pregnancy, microchimerism and autoimmunity: an update.
24431597 - Prediction of pre-eclampsia by a combination of maternal history, uterine artery dopple...
1252357 - The relationship between the course of psoriasis and transepidermal water loss, photoel...
17970797 - Assessment of glomerular filtration rate during pregnancy using the mdrd formula.
10407647 - Quantitative ultramorphological (qum) analysis of human sperm: diagnosis and management...
19508667 - Feasibility, reliability, and validity of three health-state valuation methods using mu...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Reviews in the neurosciences     Volume:  16     ISSN:  0334-1763     ISO Abbreviation:  Rev Neurosci     Publication Date:  2005  
Date Detail:
Created Date:  2006-03-07     Completed Date:  2006-03-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8711016     Medline TA:  Rev Neurosci     Country:  England    
Other Details:
Languages:  eng     Pagination:  303-10     Citation Subset:  IM    
Department of Experimental Psychology, Cambridge University, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials, Phase I as Topic
Disease Models, Animal*
Gene Therapy
Glial Cell Line-Derived Neurotrophic Factor / administration & dosage,  genetics,  therapeutic use*
Parkinson Disease / drug therapy*,  metabolism
Recombinant Proteins / administration & dosage,  genetics,  therapeutic use
Reg. No./Substance:
0/Glial Cell Line-Derived Neurotrophic Factor; 0/Recombinant Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Synaptic plasticity in the central nucleus of the amygdala.
Next Document:  The mechanisms and functions of activity-dependent long-term potentiation of intrinsic excitability.